Sanofi (SNY) News Today → Elon Musk’s PRIME is Set to Shock the World (From InvestorPlace) (Ad) Free SNY Stock Alerts $48.67 -0.15 (-0.31%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 7:24 AM | marketbeat.comJanney Montgomery Scott LLC Buys 141,889 Shares of Sanofi (NASDAQ:SNY)Janney Montgomery Scott LLC boosted its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 103.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 278,545 shares of the company's stock after bMay 17 at 8:34 PM | marketbeat.comOxbow Advisors LLC Acquires New Holdings in Sanofi (NASDAQ:SNY)Oxbow Advisors LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 94,294 shares of the company's stock, valuMay 16 at 9:43 AM | benzinga.comPfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma GameMay 14, 2024 | marketbeat.comSanofi (NASDAQ:SNY) Shares Gap Down to $50.21Sanofi (NASDAQ:SNY) Shares Gap Down to $50.21May 13, 2024 | msn.comNovavax (NASDAQ:NVAX) Explodes 50% Higher after Sanofi DealMay 13, 2024 | markets.businessinsider.comBuy Rating Upheld for Fulcrum Therapeutics Amid Sanofi Partnership and Upcoming Trial CatalystsMay 13, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Hold Rating on Sanofi (SNY)May 13, 2024 | cnbc.comNovavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine makerMay 13, 2024 | markets.businessinsider.comFulcrum Therapeutics Stock Climbs In Pre-market On License Deal With Sanofi For LosmapimodMay 13, 2024 | marketwatch.comSanofi to spend $1.08 billion on ramping up French production capabilitiesMay 13, 2024 | msn.comSanofi to invest over €1 billion in French production sitesMay 13, 2024 | markets.businessinsider.comSanofi To Invest Over EUR 1 Bln Further For Biomanufacturing In FranceMay 13, 2024 | reuters.comSanofi pledges new 1 bln euros worth of investments in French production sitesMay 13, 2024 | globenewswire.comPress Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereigntyMay 12, 2024 | marketbeat.comBoston Partners Has $648.62 Million Holdings in Sanofi (NASDAQ:SNY)Boston Partners grew its position in Sanofi (NASDAQ:SNY - Free Report) by 1.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,032,746 shares of the company's stock after buying an additional 245,68May 11, 2024 | marketbeat.comShort Interest in Sanofi (NASDAQ:SNY) Increases By 67.9%Sanofi (NASDAQ:SNY - Get Free Report) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 5,440,000 shares, a growth of 67.9% from the April 15th total of 3,240,000 shares. Approximately 0.2% of the company's stock are sold short. Based on an average daily trading volume, of 2,030,000 shares, the short-interest ratio is presently 2.7 days.May 11, 2024 | marketbeat.comPrincipal Securities Inc. Takes Position in Sanofi (NASDAQ:SNY)Principal Securities Inc. bought a new stake in Sanofi (NASDAQ:SNY - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 35,363 shares of the company's stock, valued at approximately $1,759,000. A number of other hedge fuMay 11, 2024 | americanbankingnews.comSanofi (NASDAQ:SNY) Receives Average Recommendation of "Hold" from BrokeragesMay 10, 2024 | theglobeandmail.comNovavax shares soar on license deal with Sanofi at lofty valuationMay 10, 2024 | msn.comNovavax hits a 52-week high as Sanofi deal prompts J.P. Morgan upgradeMay 10, 2024 | finance.yahoo.comFed rates, Tesla Supercharger backpedal, Novavax's 'new chapter': Market DominationMay 10, 2024 | proactiveinvestors.comNovavax shares skyrocket after billion-dollar licensing deal with SanofiMay 10, 2024 | marketwatch.comNovavax shares double on $1.4 billion deal with SanofiMay 10, 2024 | investopedia.comNovavax Stock Doubles on $1.2B Sanofi Deal for COVID-19, Flu VaccinesMay 10, 2024 | finance.yahoo.comStock markets, China tariffs, Novavax and Sanofi: 3 ThingsMay 10, 2024 | bizjournals.comNovavax's share price surges after inking co-licensing deal with pharma giantMay 10, 2024 | msn.comNovavax Surges 57% Post $1.4 Billion Sanofi Deal; Apple Boosts Data Centers with AI and Internal Chips, and More NewsMay 10, 2024 | msn.comNovavax surges as Sanofi COVID vaccine deal boosts outlookMay 10, 2024 | wsj.comNovavax Shares More Than Double on $1.4 Billion Vaccine Licensing Deal with SanofiMay 10, 2024 | barrons.comNovavax Gets $1.4 Billion Deal With Sanofi. The Stock Jumps.May 10, 2024 | prnewswire.comNovavax Reports First Quarter 2024 Financial Results and Operational HighlightsMay 10, 2024 | reuters.comFrance's Sanofi in COVID-19 vaccine deal with Novavax - statementMay 10, 2024 | prnewswire.comNovavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination VaccinesMay 10, 2024 | cnbc.comNovavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop combination shotsMay 10, 2024 | globenewswire.comPress Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccinesMay 9, 2024 | fool.comSanofi's New Drug Could Help Deliver a Big PaydayMay 9, 2024 | businesswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXMay 9, 2024 | marketbeat.comInternational Assets Investment Management LLC Invests $4.70 Million in Sanofi (NASDAQ:SNY)International Assets Investment Management LLC bought a new position in shares of Sanofi (NASDAQ:SNY - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 94,586 shares of the company's stock, valuMay 8, 2024 | msn.comSanofi chief scientific officer leaving company: reportMay 8, 2024 | msn.comPfizer to settle over 10,000 Zantac-related cancer claims: reportMay 8, 2024 | fool.comSanofi's New Cancer Drug Could Help Deliver a Big PaydayMay 8, 2024 | finance.yahoo.comSanofi SA's Dividend AnalysisMay 4, 2024 | marketbeat.comTodd Asset Management LLC Purchases 30,749 Shares of Sanofi (NASDAQ:SNY)Todd Asset Management LLC boosted its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 8.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 383,241 shares of the company's stock after purchasing an additional 30,749 shaMay 2, 2024 | marketbeat.comSanofi (NASDAQ:SNY) Sees Strong Trading VolumeSanofi (NASDAQ:SNY) Sees Unusually-High Trading VolumeMay 2, 2024 | marketbeat.comNatixis Advisors L.P. Has $122.62 Million Position in Sanofi (NASDAQ:SNY)Natixis Advisors L.P. cut its position in Sanofi (NASDAQ:SNY - Free Report) by 2.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,465,762 shares of the company's stock after selling 62,527 shares during the quarter. NatixMay 2, 2024 | msn.comRegeneron falls after Q1 miss; announces $3B share buybacksMay 2, 2024 | globenewswire.comPress Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizationsMay 1, 2024 | marketbeat.comSanofi (NASDAQ:SNY) Shares Purchased by Raymond James & AssociatesRaymond James & Associates increased its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 26.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,315,255 shares of the company's sMay 1, 2024 | seekingalpha.comSanofi Q1: Wait And See For Now (Downgrade)April 30, 2024 | finance.yahoo.comSanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Elon Musk Invents New Type of A.I. (Shocking) (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone. Click here for the full story… SNY Media Mentions By Week SNY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNY News Sentiment▼0.650.50▲Average Medical News Sentiment SNY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNY Articles This Week▼178▲SNY Articles Average Week Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: REGN News VRTX News PFE News GSK News BMY News ZTS News ABT News NVS News TAK News AZN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNY) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaObama’s Forever Term [exposed]Porter & Company4 Cryptos BETTER than BitcoinTrue Market InsidersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressProtect Your Bank Account Before It’s Too LateWeiss RatingsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
